Arbutus Biopharm Stock Price, News & Analysis

Arbutus Biopharma (ABUS) announced promising results from its IM-PROVE I Phase 2a clinical trial for imdusiran, its RNAi therapeutic for chronic hepatitis B virus (cHBV). When combined with 24 weeks of pegylated interferon and nucleos(t)ide analogue therapy, the treatment achieved a 50% functional cure rate (3/6 patients) in patients with baseline HBsAg levels below 1000 IU/mL, and a 25% overall functional cure rate (3/12 patients). The combination therapy was generally safe and well-tolerated, with no serious adverse events. The data will be presented at AASLD – The Liver Meeting® on November 18, 2024.

Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial for chronic hepatitis B treatment. The study evaluated the combination of imdusiran, VTP-300, and low-dose nivolumab. Key findings show that 23% of participants receiving the triple combination achieved HBsAg loss by Week 48, with significantly greater mean declines in HBsAg levels (p <0.017) compared to other cohorts. The treatment regimen was generally well-tolerated with no immune-related adverse events. The trial included 22 participants in Group C, with 13 eligible for nivolumab treatment.

Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the Jefferies London Healthcare Conference. The company will conduct a fireside chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST. Investors can access the live webcast through the company's investor relations website, with an archived replay available for a time after the event.

Arbutus Biopharma (ABUS) reported Q3 2024 financial results with a net loss of $19.7 million ($0.10 per share). Revenue decreased to $1.3 million from $4.7 million in Q3 2023. The company maintains a strong cash position of $130.8 million, expected to fund operations into Q4 2026.

Clinical progress includes promising data from the IM-PROVE I Phase 2a trial, where 33.3% of patients achieved HBsAg loss. The company's oral PD-L1 inhibitor, AB-101, showed positive safety data and dose-dependent receptor occupancy in healthy subjects, now advancing to cHBV patient dosing.

Arbutus Biopharma (Nasdaq: ABUS) has announced it will release its third quarter 2024 financial results and provide a corporate update on Wednesday, November 6, 2024. The company will issue a press release at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET. Arbutus is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) through its pipeline of compounds, including the RNAi therapeutic imdusiran and oral PD-L1 inhibitor AB-101.

Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.

Key findings from regular abstracts include:

• Imdusiran with interferon treatment showed distinct phases of immune biomarker signatures, with Th1 activation during imdusiran lead-in and Th2 signatures associated with HBsAg seroconversion.
• The imdusiran target site is highly conserved in cHBV subjects, with in vitro testing confirming activity against tested variants.

Imdusiran is designed to reduce all HBV viral proteins and antigens, potentially enabling immune system reawakening. It is currently in multiple Phase 2a clinical trials.

Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The company will present a fireside chat on October 8, 2024, at 1:30 pm ET.

Investors and interested parties can access the live webcast of the fireside chat through the Arbutus website at https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the company's website for a time after the event. Arbutus will also host one-on-one meetings during the conference.

Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in two upcoming investor conferences in New York:

1. H.C. Wainwright 26th Annual Global Investment Conference: Formal presentation on September 9, 2024, at 8:00 am ET

2. Baird Global Healthcare Conference: Fireside chat on September 10, 2024, at 8:30 am ET

The Arbutus management team will participate in and host one-on-one meetings at both events. Interested parties can access live webcasts of the presentation and fireside chat through the company's investor relations website. Archived replays will be available for a time after the events.

Arbutus Biopharma (ABUS) reported Q2 2024 financial results and provided updates on its hepatitis B virus (HBV) clinical programs. Key highlights include:

1. Positive data from two Phase 2a trials of imdusiran, showing 33% of patients achieved undetectable HBsAg after 48 weeks of treatment.

2. Company is prioritizing imdusiran's Phase 2b development and discontinuing HBV discovery efforts, resulting in a 40% workforce reduction.

3. Cash runway extended into Q4 2026.

4. Q2 revenue was $1.7 million, down from $4.7 million in Q2 2023.

5. Net loss of $19.8 million ($0.11 per share) compared to $17.1 million ($0.10 per share) in Q2 2023.

6. Cash, cash equivalents, and investments totaled $148.5 million as of June 30, 2024.